Open an account

Guardant Health

GH · NASDAQ

$162.59+$4.71 (+2.98%)TodayMarket closed ·
Prev close $157.88

About GH

Guardant Health, Inc. is a precision oncology company, which engages in the provision of treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. The company is headquartered in Palo Alto, California and currently employs 2,490 full-time employees. The company went IPO on 2018-10-04. The company provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. The company offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.

Employees
2,490
Headquarters
Palo Alto, California
Listed
Oct 4, 2018
Sector
Health Care
Industry
Health Care Providers & Services
Website
guardanthealth.com

GH key statistics

Market cap
21.82B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.85M
Volume
1.31M
Open price
$158.29
High today
$163.57
Low today
$155.07
52 Week high
$191.05
52 Week low
$65.96

Guardant Health (GH) at a glance

Guardant Health (GH) last traded at $162.59, with a market cap of 21.82B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $155.07 and $163.57. The current price is 4.9% above the day's low and 0.6% below its high.

Volume so far is 1.31M shares, below the average of 1.85M shares a day.

Over the past year Guardant Health has ranged from $65.96 to $191.05, and now sits 77% of the way up that range.

Guardant Health met or beat analyst EPS estimates in 1 of the last 8 quarters. In Q2 FY26 it reported -$0.42 per share against an estimate of -$0.4199.

The average analyst price target is $200.45, 23.3% above the current price, from 23 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

96%of 23 analyst ratings say Buy
  • Buy95.7%
  • Hold4.3%
  • Sell0.0%
Price target · 30 analystsAvg $200.45
Low
$108.17
Now
$162.59
High
$236.25

GH earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 1 of the last 8 quarters, by 11.9% on average.

  1. Q3 FY24: reported -$0.88 per share against an estimate of -$0.767
  2. Q4 FY24: reported -$0.90 per share against an estimate of -$0.7624
  3. Q1 FY25: reported -$0.82 per share against an estimate of -$0.8172
  4. Q2 FY25: reported -$0.80 per share against an estimate of -$0.793
  5. Q3 FY25: reported -$0.74 per share against an estimate of -$0.7236
  6. Q4 FY25: reported -$1.00 per share against an estimate of -$0.7217
  7. Q1 FY26: reported -$0.45 per share against an estimate of -$0.511
  8. Q2 FY26: reported -$0.42 per share against an estimate of -$0.4199

GH news

  • Press releaseBusiness Wire

    Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 2026

  • Press releaseBusiness Wire

    TwinStrand Biosciences Announces Second U.S. Patent Trial and Appeal Board Decision Upholding All Claims of TwinStrand’s ‘127 Patent

  • Press releaseBusiness Wire

    Guardant Health Shield Blood Test Demonstrates Leading Screening Adherence and CRC Deaths Averted Compared to Stool-Based Tests

  • Press releaseBusiness Wire

    Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer

  • Press releaseBusiness Wire

    Guardant Health to Report Third Quarter 2026 Financial Results on November 5, 2026

  • Press releaseBusiness Wire

    Guardant Health COSMOS Study Published in Cancer Research Communications Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Melanoma

  • Press releaseBusiness Wire

    Guardant Health’s Shield Blood Test Covered by EviCore by Evernorth for Colorectal Cancer Screening

  • Press releaseBusiness Wire

    Guardant Health and Collaborators to Present 20 Abstracts Highlighting Portfolio of Liquid Biopsy Tests for Early Detection and Ongoing Treatment Management at 2026 World Conference on Lung Cancer

Similar companies

Companies in the same industry as Guardant Health

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.